Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Key Points: The HIF inhibitor ACF suppresses TKI-insensitive CML stem cells. The FDA-approved drug ACF may represent a novel treatment to prevent CML relapse and, in combination with TKIs, improve remission.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization
Lee, K., Zhang, H., Qian, D. Z., Rey, S., Liu, J. O., & Semenza, G. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909353106 · Cited by 451
RetractedDruker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Hypoxia-inducible factors and the response to hypoxic stress
Majmundar, A. J., Wong, W. J., & Simon, M. C. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.09.022 · Cited by 2,380 · cited 2×
“Oxygen levels lower than 7% stabilize HIF-1α, which binds the HIF-1β subunit and drives the transcription of genes regulating energetic metabolism, cell survival/proliferation, and angiogenesis.(18) HIF-1 also drives cancer progression.”
BackgroundHIF-1 mediates metabolic responses to intratumoral hypoxia and oncogenic mutations
Semenza, G. L. (2013) · Journal of Clinical Investigation · doi:10.1172/jci67230 · Cited by 1,335 · cited 1×
“HIF-1 also drives cancer progression.(19) In CML cell populations, HIF-1α and HIFresponsive genes are up-regulated by BCR/Abl.”
BackgroundHudson, C. C., Liu, M., Chiang, G. G., Otterness, D. M., Loomis, D. C., Kaper, F., Giaccia, A. J., & Abraham, R. T. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.20.7004-7014.2002 · Cited by 1,186
Corbin, A. S., Agarwal, A., Loriaux, M., Cortes, J., Deininger, M. W., & Druker, B. J. (2011) · Journal of Clinical Investigation · doi:10.1172/jci35721 · Cited by 765
Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway
Kung, A. L., Zabludoff, S. D., France, D. S., Freedman, S. J., Tanner, E. A., Vieira, A., Cornell-Kennon, S., Lee, J., Wang, B., Wang, J., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.009 · Cited by 480
Topoisomerase I-Mediated Inhibition of Hypoxia-Inducible Factor 1
Rapisarda, A., Uranchimeg, B., Sordet, O., Pommier, Y., Shoemaker, R. H., & Melillo, G. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3139 · Cited by 301
Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells
Abraham, S. A., Hopcroft, L. E. M., Carrick, E., Drotar, M. E., Dunn, K., Williamson, A. J. K., Korfi, K., Baquero, P., Park, L. E., Scott, M. T., et al. (2016) · Nature · doi:10.1038/nature18288 · Cited by 225 · cited 1×
“The anti-proliferative effect of ACF was supported by the fact that ACF suppressed the expression of c-MYC (Figure 2D), a protooncogene important for cell cycle regulation and BCR/Abl-driven transformation.(41,42) ACF inhibited c-MYC expression at the transcriptional (data not shown) and protein expression levels, exh…”
BackgroundLi, S. H., Shin, D. H., Chun, Y.-S., Lee, M. K., Kim, M.-S., & Park, J.-W. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0074 · Cited by 160 · cited 1×
“ACF decreases HIF transcriptional activity by inhibiting the α/β dimerization;(22) YC1 inhibits HIF-1α activity by promoting its degradation, inhibiting its translation, 33 stimulating “factor inhibiting HIF” and reducing binding of p300, a co-activator indispensable for transcription initiation of HIF-1α-downstream g…”
BackgroundSelf-citation
Cited by
Response and Resistance to BCR-ABL1-Targeted Therapies
Braun, T. P., Eide, C. A., & Druker, B. J. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.03.006 · Cited by 483
Pharmacologic Targeting of Hypoxia-Inducible Factors
Semenza, G. L. (2019) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010818-021637 · Cited by 288
(2019) · Advances in Cancer Research · doi:10.1016/bs.acr.2018.11.001 · Cited by 71
Therapeutic targeting of TP53-mutated acute myeloid leukemia by inhibiting HIF-1α with echinomycin
Wang, Y., Liu, Y., Bailey, C., Zhang, H., He, M., Sun, D., Zhang, P., Parkin, B., Baer, M. R., Zheng, P., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1201-z · Cited by 38
Ex Vivo Expansion of Phenotypic and Transcriptomic Chronic Myeloid Leukemia Stem Cells
Patel, S. B., Kuznetsova, V., Matkins, V. R., Franceski, A. M., Bassal, M. A., & Welner, R. S. (2022) · Experimental Hematology · doi:10.1016/j.exphem.2022.09.001 · Cited by 7
Metadata
- Authors
- Cheloni, G., Tanturli, M., Tusa, I., Ho DeSouza, N., Shan, Y., Gozzini, A., Mazurier, F., Rovida, E., Li, S., & Dello Sbarba, P.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2017-08-03
- Volume
- 130
- Issue
- 5
- Pages
- 655-665
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2620808717
- Cited by
- 85
- References
- 11
- FWCI
- 6.15
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine. https://app.cochat.ai/papers/10.1182/blood-2016-10-745588
- The paper
- Cheloni, G., Tanturli, M., Tusa, I., Ho DeSouza, N., Shan, Y., Gozzini, A., Mazurier, F., Rovida, E., Li, S., & Dello Sbarba, P. (2017). Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine. Blood. https://doi.org/10.1182/blood-2016-10-745588
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.